Literature DB >> 8645110

Immunisation with DNA polynucleotides protects mice against lethal challenge with St. Louis encephalitis virus.

R J Phillpotts1, K Venugopal, T Brooks.   

Abstract

In vivo transfection by intramuscular injection with plasmids expressing the immunogenic proteins of microbial pathogens has considerable potential as a vaccination strategy against many pathogens of both man and animals. Here we report that weanling mice given a single intramuscular injection of 50 micrograms of a plasmid, pSLE1 expressing the St. Louis encephalitis virus (SLE) prM/E protein under the control of the cytomegalovirus immediate early protein promoter produced SLE-specific antibody and were protected against lethal challenge with the virulent virus. Polynucleotide vaccine technology provides a unique opportunity to produce vaccines against flavivirus diseases of low incidence cheaply and rapidly, and to produce multivalent vaccines such as would be required for immunisation against dengue virus disease.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8645110     DOI: 10.1007/bf01718332

Source DB:  PubMed          Journal:  Arch Virol        ISSN: 0304-8608            Impact factor:   2.574


  14 in total

Review 1.  New approaches to flavivirus vaccine development.

Authors:  J J Schlesinger; J R Putnak; K H Eckels
Journal:  Biotechnology       Date:  1992

2.  From the World Health Organization. Development of dengue and Japanese encephalitis vaccines.

Authors:  W E Brandt
Journal:  J Infect Dis       Date:  1990-09       Impact factor: 5.226

3.  Long-term persistence of plasmid DNA and foreign gene expression in mouse muscle.

Authors:  J A Wolff; J J Ludtke; G Acsadi; P Williams; A Jani
Journal:  Hum Mol Genet       Date:  1992-09       Impact factor: 6.150

4.  DNA immunization confers protection against lethal lymphocytic choriomeningitis virus infection.

Authors:  M Yokoyama; J Zhang; J L Whitton
Journal:  J Virol       Date:  1995-04       Impact factor: 5.103

Review 5.  Facilitated DNA inoculation induces anti-HIV-1 immunity in vivo.

Authors:  L Coney; B Wang; K E Ugen; J Boyer; D McCallus; V Srikantan; M Agadjanyan; C J Pachuk; K Herold; M Merva
Journal:  Vaccine       Date:  1994-12       Impact factor: 3.641

6.  Direct gene transfer in skeletal muscle: plasmid DNA-based immunization against the hepatitis B virus surface antigen.

Authors:  H L Davis; M L Michel; M Mancini; M Schleef; R G Whalen
Journal:  Vaccine       Date:  1994-12       Impact factor: 3.641

7.  3,3',5,5' - Tetramethylbenzidine as an Ames test negative chromogen for horse-radish peroxidase in enzyme-immunoassay.

Authors:  E S Bos; A A van der Doelen; N van Rooy; A H Schuurs
Journal:  J Immunoassay       Date:  1981

Review 8.  Towards a new generation of flavivirus vaccines.

Authors:  K Venugopal; E A Gould
Journal:  Vaccine       Date:  1994-08       Impact factor: 3.641

9.  Immunity to St. Louis encephalitis virus by sequential immunization with recombinant vaccinia and baculovirus derived PrM/E proteins.

Authors:  K Venugopal; W R Jiang; E A Gould
Journal:  Vaccine       Date:  1995-08       Impact factor: 3.641

10.  Constitutive and enhanced expression from the CMV major IE promoter in a defective adenovirus vector.

Authors:  G W Wilkinson; A Akrigg
Journal:  Nucleic Acids Res       Date:  1992-05-11       Impact factor: 16.971

View more
  17 in total

1.  Increased immune response elicited by DNA vaccination with a synthetic gp120 sequence with optimized codon usage.

Authors:  S André; B Seed; J Eberle; W Schraut; A Bültmann; J Haas
Journal:  J Virol       Date:  1998-02       Impact factor: 5.103

2.  Induction of protective immunity against Japanese encephalitis in mice by immunization with a plasmid encoding Japanese encephalitis virus premembrane and envelope genes.

Authors:  E Konishi; M Yamaoka; I Kurane; P W Mason
Journal:  J Virol       Date:  1998-06       Impact factor: 5.103

3.  A Measles Virus-Based Vaccine Candidate Mediates Protection against Zika Virus in an Allogeneic Mouse Pregnancy Model.

Authors:  Cindy Nürnberger; Bianca S Bodmer; Anna H Fiedler; Gülsah Gabriel; Michael D Mühlebach
Journal:  J Virol       Date:  2019-01-17       Impact factor: 5.103

4.  The anamnestic neutralizing antibody response is critical for protection of mice from challenge following vaccination with a plasmid encoding the Japanese encephalitis virus premembrane and envelope genes.

Authors:  E Konishi; M Yamaoka; I Kurane; K Takada; P W Mason
Journal:  J Virol       Date:  1999-07       Impact factor: 5.103

5.  Screening of protective antigens of Japanese encephalitis virus by DNA immunization: a comparative study with conventional viral vaccines.

Authors:  H W Chen; C H Pan; M Y Liau; R Jou; C J Tsai; H J Wu; Y L Lin; M H Tao
Journal:  J Virol       Date:  1999-12       Impact factor: 5.103

6.  Production and characterization of vaccines based on flaviviruses defective in replication.

Authors:  Peter W Mason; Alexandr V Shustov; Ilya Frolov
Journal:  Virology       Date:  2006-05-18       Impact factor: 3.616

7.  A single intramuscular injection of recombinant plasmid DNA induces protective immunity and prevents Japanese encephalitis in mice.

Authors:  G J Chang; A R Hunt; B Davis
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

8.  Production of pseudoinfectious yellow fever virus with a two-component genome.

Authors:  Alexandr V Shustov; Peter W Mason; Ilya Frolov
Journal:  J Virol       Date:  2007-08-22       Impact factor: 5.103

9.  The relative contribution of antibody and CD8+ T cells to vaccine immunity against West Nile encephalitis virus.

Authors:  Bimmi Shrestha; Terry Ng; Hsien-Jue Chu; Michelle Noll; Michael S Diamond
Journal:  Vaccine       Date:  2008-02-20       Impact factor: 3.641

10.  Inoculation of plasmids encoding Japanese encephalitis virus PrM-E proteins with colloidal gold elicits a protective immune response in BALB/c mice.

Authors:  Zijiang Zhao; Takaji Wakita; Kotaro Yasui
Journal:  J Virol       Date:  2003-04       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.